Sema4 Stock

sema4.comHealthcare / Healthcare providers & servicesFounded: 2015Funding to Date: $368.26MM

Sema4 is the developer of an AI-driven patient-centered genomic and clinical data insight platform designed to to transform healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology.

Register To Buy and Sell Shares

For more details on financing and valuation for Sema4, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Sema4’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Sema4.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

News Highlights

Sema4 to Study Precision Oncology Disparities in Nationwide Biobanking, Genomic Profiling Study
The firm will use its suite of assays to characterize samples from 5,000 advanced cancer patients from underserved communities and create a representative biobank.
Sema4 Q4 Revenues Decline 10 Percent
Sema4 beat the consensus Wall Street estimate on the top and bottom lines for Q4 and said it expects between $215 million and $225 million in revenues for 2022.
Updated on: Feb 27, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.